Home  /  Resource Library  /  Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma

Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma

Indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for treatment of relapsed DLBCL.